Previous 10 |
home / stock / dskyf / dskyf news
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors still have trade handicapping on the agenda next week as talks between th...
Daiichi Sankyo ( OTCPK:DSKYF ) and collaboration partner AstraZeneca (NYSE: AZN ) announce positive results from an open-label Phase 2 clinical trial, DESTINY-Breast01 , evaluating trastuzumab deruxtecan (DS-8201) in HER2-positive, unresectable/metastatic breast cancer patients previ...
Introduction In this edition of the Focus on Europe series, we are having a closer look at a small-cap (110M EUR market cap) in Belgium that doesn’t even have an OTC or pink sheets listing. Its IPO in 2017 was hyped, but the share price has lost approximately 80% since then as all h...
By Breakingviews AstraZeneca (AZN) is taking a precision approach in the race to treat cancer. The UK drugmaker on Thursday evening said it will pay up to $6.9 billion to work with Daiichi Sankyo (DSKYF) on a treatment for breast cancer. Compared to the risk of an acquisition, it’s ...
The year 2019 is an exciting time for Rigel Pharmaceuticals ( RIGL ) in many ways and not so much in others. On the one hand, the company will generate its first full year of sales data from Tavalisse (fostamatinib) which it began marketing for chronic immune thrombocytopenia ((ITP)) in late...
- Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 CLEAR Wisdom at the American College of Cardiology (ACC) 2019 Scientific Sessions - Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated and Adverse Event Profile was Similar to that of Plac...
MUNICH , March 18, 2019 /PRNewswire/ -- ELIMINATE-AF is the first set of data presented in 2019 from the Edoxaban Clinical Research Programme, which will deliver new evidence to support the use of edoxaban in clinical practice Late-breaking data presented at EHRA 2019, the annual ...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...